Senti Biosciences

68 articles about Senti Biosciences

• Senti Bio to Participate in Upcoming September 2023 Investor Conferences

  9/5/2023

  Senti Biosciences, Inc., a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, announced its participation at the following investor conferences.

• Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates

  8/11/2023

  Senti Biosciences, Inc., a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, reported financial results for the second quarter of 2023.

• Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners

  8/10/2023

  Senti Biosciences, Inc. today announced a transaction involving GeneFab, LLC (“GeneFab”), a new independent contract manufacturing and synthetic biology biofoundry focused on next-generation cell and gene therapies backed by Celadon Partners.

• GeneFab Launches to Offer Innovative Manufacturing and Synthetic Biology Design Services for a Broad Range of Genetic Medicines

  8/10/2023

  GeneFab, LLC, a contract research, development and manufacturing organization partnering with the cell and gene therapy industry and backed by private equity firm Celadon Partners, LLC, announced a transaction with Senti Biosciences, Inc. in which GeneFab would sublease Senti Bio’s current good manufacturing practice facility, a portion of which is subject to certain conditions.

• Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

  5/20/2023

  Senti Biosciences, Inc. announced multiple presentations highlighting the broad application of its Gene Circuit technologies in multiple modalities at the American Society of Gene and Cell Therapy annual meeting in Los Angeles, CA.

• Senti Bio Announces First Quarter 2023 Results and Pipeline Updates

  5/9/2023

  Senti Biosciences, Inc., a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, reported financial results for the first quarter of 2023.

• Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting

  5/2/2023

  Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”) today announced two oral presentations and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, being held May 16-20, 2023, in Los Angeles, CA.

• Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting

  4/17/2023

  Senti Biosciences, Inc. today announced the presentation of preclinical data from multiple wholly-owned pipeline programs at the American Association for Cancer Research (AACR) Annual Meeting being held April 14-19, 2023, in Orlando, Florida.

• Senti Bio to Participate in Upcoming Investor Conferences - April 14, 2023

  4/14/2023

  Senti Biosciences, Inc., a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, announced its participation at the following investor conferences.

• Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights

  3/22/2023

  Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter and full year ended December 31, 2022.

• Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting

  3/14/2023

  Senti Biosciences, Inc., a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, announced the acceptance of three abstracts for presentation at the American Association for Cancer Research Annual Meeting being held April 14-19, 2023, in Orlando, Florida.

• Senti Biosciences Announces New Employment Inducement Grants - February 03, 2023

  2/3/2023

  Senti Biosciences, Inc. announced that effective on February 1, 2023, the Compensation Committee of Senti Bio’s Board of Directors granted to 13 new employees stock options to purchase an aggregate of 309,000 shares of the Company’s common stock with a per share exercise price of $1.81.

• Senti Bio to Present at the SVB Securities Global Biopharma Conference

  2/1/2023

  Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit technology platform, today announced that Tim Lu, MD, PhD, Senti’s Co-Founder and CEO, will present at the SVB Securities Global Biopharma Conference.

• Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance

  1/27/2023

  Senti Biosciences, Inc. announced a strategic plan to focus internal resources on SENTI-202, SENTI-401 and, with potential partners, to continue to pursue the development of Gene Circuits for other programs, including solid tumors.

• Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference

  12/19/2022

  Senti Biosciences, Inc. today announced that Tim Lu, MD, PhD, Co-founder and Chief Executive Officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 5:15 p.m. PT.

• Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event

  12/11/2022

  Senti Biosciences, Inc., a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, announced a presentation at the American Society of Hematology Annual Meeting in New Orleans.

• Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting

  11/23/2022

  Senti Biosciences, Inc. will host an Investor Event on December 11 during the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, LA.

• Senti Bio Reports Third Quarter Financial Results and Pipeline Updates

  11/10/2022

  Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today reported financial results for the third quarter ended September 30, 2022.

• Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting

  11/3/2022

  Senti Biosciences, Inc. announced a poster presentation at the 64th American Society of Hematology Annual Meeting, being held December 10-13, 2022, in New Orleans, LA.

• Senti Bio Announces New Employment Inducement Grants - October 28, 2022

  10/28/2022

  Senti Biosciences, Inc. announced that on October 27, 2022, the compensation committee of Senti Bio’s board of directors granted to 9 new employees stock options to purchase an aggregate of 200,200 shares of the Company’s common stock with a per share exercise price of $2.39.